Affimed N.V. Overview
Pro stress-test →Affimed is a clinical-stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies. The company's proprietary, next-generation bispecific antibodies, called TandAbs, are designed to direct and establish a bridge between either NK-cells or T-cells and cancer cells, triggering a signal cascade that leads to the destruction of cancer cells. The company develops novel immuno-oncology therapeutics leveraging innate immune mechanisms for multiple cancer indications.
Strategic Profile
Pro stress-test →Affimed collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers. The company has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK, and a strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology. These partnerships position Affimed to advance multiple programs while managing development risk and accessing complementary capabilities.
Competitive Landscape
Pro stress-test →Affimed's NK cell and T-cell engager platform competes in the immuno-oncology space, where bispecific antibody technology bridges immune effector cells to cancer targets. Key competitors include Genmab, Regeneron, Amgen, and Astellas in bispecific antibody and NK cell engager development. Affimed's partnerships with Genentech and others reflect industry consolidation and co-development strategies common in clinical-stage oncology.
Industry Context
Affimed N.V. operates in Cancer immunotherapy biopharmaceuticals.
Key facts
Founded: 2000 · Headquarters: Heidelberg, Germany · Employees: N/A · Revenue: Estimated $0–$10M (clinical-stage; no product revenues) · Market cap: N/A